ArticleHepatology forum2026
Artificial intelligence-based multiclass classification of etiologies in patients with elevated liver enzymes: A prospective cohort study.
Article in Hepatology forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Elevated liver enzymes are a common reason for hepatology referral, but etiological overlap complicates diagnosis. Most artificial intelligence applications address binary tasks, whereas routine practice requires multiclass discrimination. We developed and internally validated an explainable multiclass model to differentiate five major causes of persistent liver enzyme elevation. Materials and Methods: This prospective proof-of-concept cohort included 280 consecutive adults with unexplained persistent aminotransferase elevation. Final diagnoses-metabolic dysfunction-associated steatotic liver disease, viral hepatitis, alcohol-related liver disease, drug-induced liver injury, or autoimmune hepatitis-were independently adjudicated by three hepatologists. Data were split into training (70%) and independent test (30%) sets, and four supervised algorithms were evaluated. To assess incorporation bias, a basic model using routine clinical and biochemical variables was compared with an extended model including serological markers. Interpretability was assessed using SHapley Additive exPlanations. Results: eXtreme gradient boosting achieved the best test-set performance, with an overall accuracy of 0.86 (95% CI 0.78-0.93) and balanced accuracy of 0.87 (95% CI 0.82-0.92). Class-specific AUROC values ranged from 0.92 to 0.95. Serological markers improved discrimination for autoimmune hepatitis (AUROC increase, 0.15; p<0.03) and viral hepatitis (increase, 0.11; p<0.02). Interpretability analysis identified clinically plausible predictors. Misclassifications occurred in 12 cases (14.3%), mainly in overlapping drug-induced liver injury-autoimmune hepatitis presentations. Conclusion: An explainable multiclass model differentiated five major etiologies of persistent liver enzyme elevation. Serological markers added value for autoimmune and viral etiologies. External validation is required before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.